PALLIATIVE JAW-SPARING TREATMENT OF A NON-RESECTABLE CANINE ORAL FIBROSARCOMA USING COMBINATION OF ELECTROCHEMOTHERAPY WITH BLEOMYCIN AND IL-12 GENE ELECTROTRANSFER

Authors

  • Darja Pavlin Veterinary faculty Ljubljana
  • Ana Nemec Veterinary faculty Ljubljana
  • Urša Lampreht Tratar Institute of Oncology Ljubljana
  • Maja Čemazar Institute of Oncology Ljubljana
  • Andreja Brožič Institute of Oncology Ljubljana
  • Gregor Serša Institute of Oncology Ljubljana
  • Nataša Tozon Veterinary faculty Ljubljana

DOI:

https://doi.org/10.26873/SVR-1148-2020

Abstract

A 15-year- old male castrated English setter was presented for evaluation of a rapidly growing oral mass. Patient’s history was otherwise unremarkable, except of moderate proteinuria of 5 years duration. Clinical examination findings were within normal limits, except of an ulcerated located at the left mandibular canine tooth, which was histologically confirmed as a high grade infiltrative fibrosarcoma with high mitotic index (61/10 HPF) and multifocal necrotic areas. The client declined full staging, so only hematological and biochemistry examinations of blood were performed, which were without any clinically significant alterations. Furthermore a fine needle aspiration biopsy of regional lymph nodes was performed, which revealed reactive lymphadenopathy without signs of metastases. After declining other more invasive therapeutic procedures, the clients elected treatment with combination of electrochemotherapy and IL-12 electrogene therapy. Four consecutive treatment sessions were performed, resulting not only in complete response of the primary tumor, but also in regression of untreated distant metastasis, which was diagnosed approximately one month after the initial examination.  Furthermore, the percentage of circulating CD8+ cells was increased after each therapy session, indicating possible systemic induction of immune response by IL-12 gene therapy. This case shows that this type of therapy can represent an alternative type of both local and systemic treatment in selected tumor cases, where clients seek a less invasive nonsurgical treatment.

Key words: dog; fibrosarcoma; electroporation; electrochemotherapy; electrogene therepy, interleukin-12

 

PALIATIVNO ZDRAVLJENJE NERESEKTABILNEGA FIBROSARKOMA SPODNJE ČELJUSTI PRI PSU S KOMBINACIJO ELEKTROKEMOTERAPIJE Z BLEOMICINOM IN GENSKEGA ELEKTROPRENOSA IL-12

Izvleček: Petnajstleni kastrirani angleški seter je bil na našo kliniko sprejet z namenom pregleda hitro rastoče novotvorbe v ustni votlini. Pes ni imel pomembnejših sočasnih bolezni, razen zmerne proteinurije zadnjih pet let. Fizikalni pregled ni pokazal nikakršnih odstopanj z izjemo ulcerirane novotvorbe na področju levega mandibularnega grabilca. Histološka diagnoza novotvorbe je bila infiltrativni fibrosarkom visoke stopnje z visokim mitotičnim indeksom (61/10 v polju visoke povečave) in multifokalnimi nekrotičnimi področji. Skrbnik psa je zavrnil popolno določitev stadija bolezni, zato smo izvedli le osnovne hematološke in biokemijske preisakve, ki niso pokazale pomembnejših odstopanj. Izvedli smo tudi tankoligelno biopsijo regionalnih bezgavk, ki je pokazala reaktivno limfadenopatijo brez znakov prisotnosti zasevkov. Po predstavitvi vseh možnosti zdravljenja se je lastnik odločil za zdravljenje s kombinacijo elektrokemoterapije in genskega elektroprenosa IL-12. Izvedli smo štiri zaporedne cikluse kombinirane terapije, s katero smo dosegli ne le popolni odgovor primarnega tumorja, pač pa tudi regresijo nezdravljenih oddaljenih podkožnih metastaz, ki so se pojavile približno mesec dni po začetku terapije. Poleg tega smo po vsaki terapiji ugotovili povečan delež cirkulirajočih CD8+ celic, kar lahko nakazuje na to, da je genska terapija z IL-12 sprožila sistemski imunski odziv. Predstavljeni primer kaže, da lahko kombinacija elektrokemoterapije in genskega elektroprenosa IL-12 predstavlja alternativno obliko tako lokalnega kot sistemskega zdravljenja določenih novotvorb, zlasti v primerih, ko skrbnik živali želi manj invazivne terapevtske postopke.

Ključne besede: pes; fibrosarkom; elektroporacija; elektrokemoterapija, genski eletroprenos; interlevkin-12

References

(1.) Head KW. Histologic classification of the tumors of the alimentary system of domestic animals. Washington : Armed Forces Institute of Pathology, American Registry of Pathology, World Health Organization, 2003. (International Classification of Tumors of Domestic Animals, 2nd ser ., Vol. 10)

(2.) Lommer MJ, Verstraete FJM. Principals of oral oncologic surgery. In: Verstraete FJM, Lommer MJ, eds. Oral and maxillofacial surgery in dogs and cats. Edinburgh : Saunders Elsevier, 2012: 423–30.

(3.) Frazier SA, Johns SM, Ortega J, et al. Outcome in dogs with surgically resected oral fibrosarcoma (1997–2008). Vet Comp Oncol 2012; 10: 33–43.

(4.) Gardner H, Fidel J, Haldorson G, Dernell W, Wheeler B. Canine oral fibrosarcomas: a retrospective analysis of 65 cases (1998–2010). Vet Comp Oncol 2013; 13: 40–7.

(5.) Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008; 423: 319–25.

(6.) Cemazar M, Tamzali Y, Sersa G, et al. Electrochemotherapy in veterinary oncology. J Vet Intern Med 2008; 22: 826–31.

(7.) Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993; 151: 2444–52.

(8.) Maher J, Davies ET. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer 2004; 91: 817–21.

(9.) Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2: 735–47.

(10.) Kodre V, Cemazar M, Pecar J Sersa G, Cor A, Tozon N. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo 2009; 23: 55–62.

(11.) Cemazar M, Ambrozic Avgustin J, Pavlin D, et al. Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. Vet Comp Oncol 2017; 15(2): 641–54. doi: 10.1111/vco.12208.

(12.) Tozon N, Pavlin D, Sersa G, et al. Electrochemotherapy with intravenous bleomycin injection: an observational study in superficial squamous cell carcinoma in cats. J Feline Med Surg 2014; 16: 291–9.

(13.) Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4–16.

(14.) Spugnini EP, Azzarito T, Fais S, Fanciulli M, Baldi A. Electrochemotherapy as first line cancer treatment: Experiences from veterinary medicine in developing novel protocols. Curr Cancer Drug Targets 2015; 16: 43–52.

(15.) Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 2011; 45: 31–9.

(16.) Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002; 5: 668–75.

(17.) Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogačnik A, Serša G. Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 2009; 8: 2114–22.

(18.) Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16: 191–9.

(19.) Calvet CY, Famin D, André FM, et al. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 2014; 3: e28131. doi: 10.4161/onci.28131

(20.) Sersa G, Teissie J, Cemazar M, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315–27.

(21.) Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896–903.

(22.) Cutrera J, King G, Jones P, et al. Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy. J Cell Mol Med 2015; 19: 664–75.

(23.) O'Neill K, Guth A, Biller B, Elmslie R, Dow S. Changes in regulatory T cells in dogs with cancer and associations with tumor type. J Vet Intern Med 2009; 23: 875–81.

(24.) Fridman WH, Pagès F, Sautès-Fridman C, Galon L. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.

(25.) Giraldo NA, Becht E, Remark R, Damotte D, Sautès-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014; 27: 8–15.

(26.) Oliveira PH, Mairhofer J. Marker-free plasmids for biotechnological applications: implications and perspectives. Trends Biotechnol 2013; 31: 539–47.

Downloads

Published

2021-03-24

How to Cite

Pavlin, D., Nemec, A., Lampreht Tratar, U., Čemazar, M., Brožič, A., Serša, G., & Tozon, N. (2021). PALLIATIVE JAW-SPARING TREATMENT OF A NON-RESECTABLE CANINE ORAL FIBROSARCOMA USING COMBINATION OF ELECTROCHEMOTHERAPY WITH BLEOMYCIN AND IL-12 GENE ELECTROTRANSFER. SLOVENIAN VETERINARY RESEARCH, 58(1). https://doi.org/10.26873/SVR-1148-2020

Issue

Section

Case Report